CATECHOL-O-METHYLTRANSFERASE (COMT) INHIBITOR
Ongentys is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat people with Parkinson’s experiencing “off” episodes. Ongentys is also referred to by its drug name, opicapone.
Ongentys is used as an adjunctive treatment to levodopa and carbidopa for Parkinson’s. Ongentys is a member of a class of drugs called catechol-O-methyltransferase (COMT) inhibitors. Ongentys is believed to work by preventing the body from breaking down levodopa. This helps more levodopa enter the brain and turn into dopamine, which protects against symptoms of Parkinson’s.
How do I take it?
Prescribing information states that Ongentys is taken orally once per day.
Ongentys comes in capsule form.
The FDA-approved label for Ongentys lists common side effects including uncontrollable movements, low blood pressure, dizziness or fainting, dry mouth, constipation, and weight loss.
Rare but serious side effects listed for Ongentys include heart problems, hallucinations, impulse control disorders, falling asleep during daily tasks, low blood pressure, and confusion.
For more details about this treatment, visit:
Ongentys — Neurocrine Biosciences
Ongentys — The Michael J. Fox Foundation
We never share your personal information with anyone.
Want to stay up to date on the latest news and articles about Parkinson's disease?